Paolo Zucali

Associate Professor of Medical Oncology

Humanitas University

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Paolo Zucali is an Associate Professor of Medical Oncology at Humanitas University in Italy. His research focuses on precision medicine and innovative therapies in oncology, particularly in the areas of malignant mesothelioma, prostate cancer, and renal cell carcinoma. Recent publications include reviews on emerging radiopharmaceuticals and the prognostic impact of treatment interventions. He is actively involved in advancing understanding and treatment options for various malignancies.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (10)

Elisa Giovannetti

NETHERLANDS

View details

Godefridus J Peters

Professor

Medical University of Gdansk

POLAND

View details

Fabio Grizzi

Head Histology Core

IRCCS Humanitas Research Hospital

ITALY

View details

Serena Di Cosimo

Open University

UNITED KINGDOM

View details

Maurizio D'Incalci

Head

IRCCS Humanitas Research Hospital

ITALY

View details

marco alloisio

Humanitas University

ITALY

View details

Sara Manglaviti

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Ryszard T. Smolenski

Medical University of Gdansk

POLAND

View details

DANIELE GENERALI

University of Trieste

ITALY

View details

Giuseppe Luigi Banna

Honorary Associate Professor

University of Portsmouth

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Paolo Zucali

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study

Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives

Advancing Prostate Cancer Care: Prostate-specific Membrane Antigen–based Radioligand Therapy at the Forefront

Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab

The Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for ThYmic MalignanciEs (TYME)

Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs

A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study

Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients’ selection

Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice

Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study

Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study

Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study

Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)

Collaborators (10)

Elisa Giovannetti

Godefridus J Peters

Fabio Grizzi

Serena Di Cosimo

Maurizio D'Incalci

marco alloisio

Sara Manglaviti

Ryszard T. Smolenski

DANIELE GENERALI

Giuseppe Luigi Banna

Make your next move.